The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-patient phase I study of BGB324, a selective Axl kinase inhibitor in patients with refractory/relapsed AML and high-risk MDS.
 
Sonja Loges
Research Funding - BerGenBio
Travel, Accommodations, Expenses - BerGenBio
 
Bjorn Torre Gjertsen
Leadership - KinDex
Stock and Other Ownership Interests - KinDex
Research Funding - BerGenBio; KinDex
Travel, Accommodations, Expenses - BerGenBio
 
Michael Heuser
Consulting or Advisory Role - BerGenBio
 
I Ben-Batalla
Research Funding - BerGenBio
 
David Micklem
Employment - BerGenBio
Leadership - BerGenBio
Stock and Other Ownership Interests - BerGenBio
 
Chromik Jorg
No Relationships to Disclose
 
Maxim Kebenko
No Relationships to Disclose
 
Walter M. Fiedler
No Relationships to Disclose
 
Jorge E. Cortes
Consulting or Advisory Role - Ambit BioSciences; Amphivena Therapeutics; ARIAD; Astellas Pharma; BiolineRx; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Ambit BioSciences (Inst); ARIAD (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Teva (Inst)